CardioGenics Holdings Inc

PINK:CGNH USA Diagnostics & Research
Market Cap
$9.61K
Market Cap Rank
#45049 Global
#14202 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$0.25
About

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market. Its products include QL Care Analyzer, which is a portable, stand-alone, and automated POC immunoanalyzer; a series of immunoassay tests to enhance the management of patients with cardiovascular diseases; and paramagnetic beads that are used as a sol… Read more

CardioGenics Holdings Inc (CGNH) - Total Assets

Latest total assets as of January 2016: $558.45K USD

Based on the latest financial reports, CardioGenics Holdings Inc (CGNH) holds total assets worth $558.45K USD as of January 2016.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

CardioGenics Holdings Inc - Total Assets Trend (2000–2015)

This chart illustrates how CardioGenics Holdings Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

CardioGenics Holdings Inc - Asset Composition Analysis

Current Asset Composition (October 2015)

CardioGenics Holdings Inc's total assets of $558.45K consist of 22.5% current assets and 77.5% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 21.5%
Accounts Receivable $2.38K 1.0%
Inventory $-2.38K -1.0%
Property, Plant & Equipment $35.17K 15.2%
Intangible Assets $102.94K 44.4%
Goodwill $0.00 0.0%

Asset Composition Trend (2000–2015)

This chart illustrates how CardioGenics Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: CardioGenics Holdings Inc's current assets represent 22.5% of total assets in 2015, a decrease from 43.2% in 2000.
  • Cash Position: Cash and equivalents constituted 21.5% of total assets in 2015, up from 18.9% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, an increase from 12.0% in 2000.
  • Asset Diversification: The largest asset category is intangible assets at 44.4% of total assets.

CardioGenics Holdings Inc Competitors by Total Assets

Key competitors of CardioGenics Holdings Inc based on total assets are shown below.

Company Country Total Assets
ADCNF
OTCGREY:ADCNF
USA $4.51 Billion
Berry Genomics Co Ltd
SHE:000710
China CN¥2.34 Billion
Malaysian Genomics Resource
KLSE:0155
Malaysia RM20.70 Million
NSN Co. Ltd
KQ:031860
Korea ₩60.96 Billion
JOONGANG DNM Co.Ltd
KQ:051980
Korea ₩121.79 Billion
GeneMatrix Inc
KQ:109820
Korea ₩28.03 Billion
Genoray Co. Ltd
KQ:122310
Korea ₩125.67 Billion
Green Cross Lab Cell Corporation
KQ:144510
Korea ₩565.79 Billion

CardioGenics Holdings Inc - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.00 - 1.51

Lower asset utilization - CardioGenics Holdings Inc generates 0.00x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: -8764.60% - -135.74%

Negative ROA - CardioGenics Holdings Inc is currently not profitable relative to its asset base.

CardioGenics Holdings Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.16 0.05 3.44
Quick Ratio 0.33 0.05 3.44
Cash Ratio 0.00 0.00 0.00
Working Capital $-1.96 Million $ -1.73 Million $ 1.17 Million

CardioGenics Holdings Inc - Advanced Valuation Insights

This section examines the relationship between CardioGenics Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio -
Latest Market Cap to Assets Ratio 0.04
Asset Growth Rate (YoY) -14.1%
Total Assets $231.93K
Market Capitalization $9.61K USD

Valuation Analysis

Below Book Valuation: The market values CardioGenics Holdings Inc's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: CardioGenics Holdings Inc's assets decreased by 14.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for CardioGenics Holdings Inc (2000–2015)

The table below shows the annual total assets of CardioGenics Holdings Inc from 2000 to 2015.

Year Total Assets Change
2015-10-31 $231.93K -14.08%
2014-10-31 $269.93K -50.74%
2013-10-31 $547.95K +43.44%
2012-10-31 $382.01K -86.62%
2011-10-31 $2.85 Million +14.81%
2010-10-31 $2.49 Million -13.89%
2009-10-31 $2.89 Million +551.61%
2008-10-31 $443.10K +229.81%
2007-10-31 $134.35K -76.77%
2006-10-31 $578.23K -31.01%
2005-10-31 $838.10K +65.18%
2004-10-31 $507.37K -5.63%
2003-10-31 $537.65K +258.64%
2002-10-31 $149.91K -74.99%
2001-10-31 $599.42K -85.94%
2000-10-31 $4.26 Million --